Aortic valve replacement (AVR) — either surgical or transcatheter — remains the only treatment demonstrated to reduce mortality and morbidity in patients with aortic stenosis. Current guidelines from the American College of Cardiology/American Heart Association (ACC/AHA) are clear on the appropriateness of AVR in symptomatic patients, but management of asymptomatic cases is less definitive.

In the setting of asymptomatic severe aortic stenosis — defined as peak aortic jet velocity ≥ 4 m/s and mean pressure gradient ≥ 40 mm Hg — AVR is recommended by the ACC/AHA guidelines if any of the following apply:

• Left ventricular ejection fraction (LVEF) is below 50 percent.
• The patient is undergoing cardiac surgery for another indication.
• Symptoms arise during exercise stress testing.The guidelines note that AVR is reasonable in cases of severe aortic stenosis in which either of the following apply:
  • Peak aortic jet velocity is greater than 5 m/s, mean pressure gradient is greater than 60 mm Hg and the patient is at low surgical risk.
  • The patient has reduced exercise tolerance or an exercise-induced reduction in blood pressure.

  Finally, the guidelines say that AVR may be considered in patients at high risk for rapid disease progression and at low surgical risk as well as in patients whose peak aortic jet velocity is rising by more than 0.3 m/s per year and who are at low surgical risk.

  A need to go beyond LVEF and traditional measures

  The new paper in Cleveland Clinic Journal of Medicine notes that assessment of asymptomatic aortic stenosis has relied on traditional echocardiographic measures of severity — namely, jet velocity, valve area, pressure gradient and LVEF.

  While echo remains the best-established and most important initial tool in aortic stenosis assessment, its limitations figure into some of the gray areas in the ACC/AHA guidelines outlined above — as well as gray areas in similar European guidelines.

  For instance, the paper cites the limitations of LVEF as a marker of left ventricular function, noting that it reflects change in ventricular cavity volume but not in the complex structure of the ventricle. “Several studies demonstrate that up to one-third of patients with severe aortic stenosis have considerable impairment of intrinsic myocardial systolic function despite a preserved ejection fraction,” notes Dr. Phelan.

  Four additional variables proposed

  In the context of this limitation, Dr. Phelan and his coauthors propose four additional variables for consideration in evaluating the effect of severe aortic stenosis on left ventricular function in the setting of a normal LVEF, none of which are included in current ACC/AHA guidelines:

  • Left ventricular hypertrophy
  • Left atrial size (as a result of elevated left atrial pressure)
  • Levels of B-type natriuretic peptide
  • Global left ventricular longitudinal strain

  After reviewing evidence in support of the incremental prognostic value of each of these variables in this setting, the authors envision a potential future revision to guidelines for asymptomatic aortic stenosis in which AVR may be considered if any of the following apply:

  • Left ventricular hypertrophy (> 15 mm wall thickness) is present.
  • The mean pressure gradient rises by more than 20 mm Hg on exercise testing.
  • B-type natriuretic peptide level is elevated (> 130 pg/mL).
  • Reduced global left ventricular strain (< 15.9 percent) is present.